Paediatric safety of azithromycin: Worldwide experience

Journal of Antimicrobial Chemotherapy

Volumn 37, Issue SUPPL. C, 1996, Pages 143-149

  Treadway, G ^a   Pontani, D ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; AZITHROMYCIN; CEFACLOR; CEFIXIME; CLARITHROMYCIN; CLOXACILLIN; ERYTHROMYCIN; MACROLIDE; PENICILLIN V; ROXITHROMYCIN;

ADOLESCENT; AFRICA; ARTICLE; ASIA; BACTERIAL INFECTION; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EUROPE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; SOUTH AMERICA;

EID: 0029812510     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/37.suppl_c.143     Document Type: Article

References (15)

1. Aronoff, S. C., Laurent, C. & Jacobs, M. R. (1987). In-vitro activity of erythromycin, roxithromycin and CP-62,993 against common pediatric pathogens. Journal of Antimicrobial Chemotherapy 19, 275-6.
2. Dunkin, K. T., Jones, S. & Howard, A. J. (1988). The in-vitro activity of CP-62,993 against Haemophilus influenzae, Branhamella catarrhalis, staphylococci and streptococci. Journal of Antimicrobial Chemotherapy 21, 405-11.
3. Fernandes, P. B. & Hardy, D. J. (1988). Comparative in vitro potencies of nine new macrolides. Drugs under Experimental and Clinical Research 14, 445-51.
4. Foulds, G., Shepard, R. M. & Johnson, R. B. (1990). The pharmacokinetics of azithromycin in human serum and tissues. Journal of Antimicrobial Chemotherapy 25, Suppl. A, 73-82.
5. Girard, A. E., Girard, D., English, A. R., Gootz, T. D., Cimochowski, C. R., Faiella, J. A. et al. (1987). Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with extended half-life and excellent tissue distribution. Antimicrobial Agents and Chemotherapy 31, 1948-54.
6. Goldstein, F. W., Emirian, M. F., Coutrot, A. & Acar, J, F. (1990). Bacteriostatic and bactericidal activity of azithromycin against Haemophilus influenzae. Journal of Antimicrobial Chemotherapy 25, Suppl. A, 25-8.
7. Hardy, D. J., Hensey, D. M., Beyer, J. M., Vojtko, C., McDonald, E. J. & Fernandes, P. B. (1988). Comparative in vitro activity of new 14-, 15- and 16-membered macrolides. Antimicrobial Agents and Chemotherapy 32, 1710-9.
8. Hopkins, S. (1991). Clinical toleration and safety of azithromycin. American Journal of Medicine 91, Suppl. 3A, 40-5.
9. Hopkins, S. (1993). Clinical safety and tolerance of azithromycin in children. Journal of Antimicrobial Chemotherapy 31, Suppl. E, 111-7.
10. Hopkins, S. (1994). Clinical toleration and safety of azithromycin in adults and children. Reviews in Contemporary Pharmacotherapy 5, 383-9.
11. Neu, H. C., Chin, N. X., Saha, G. & Labthavokul, P. (1988). Comparative in vitro activity of the new oral macrolide azithromycin. European Journal of Clinical Microbiology and Infectious Diseases 7, 541-4.
12. Pukander, J. & Rautianen, M. (1996). Penetration of azithromycin into middle ear effusion in acute and secretory otitis media in children. Journal of Antimicrobial Chemotherapy 37, Suppl. C, 53-61.
13. Retsema, J., Girard, A., Schelkly, W., Manousis, M., Anderson, M., Bright, G. et al. (1987). Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against Gram-negative organisms. Antimicrobial Agents and Chemotherapy 31, 1939-47.
14. Vaudaux, B. P., Cherpillod, J. & Dayer, P. (1996). Concentrations of azithromycin in tonsillar and/or adenoid tissue from paediatric patients. Journal of Antimicrobial Chemotherapy 37, Suppl. C, 45-51.
15. Washington, J. A. & Wilson, W. R. (1985). Erythromycin: a microbial and clinical perspective after 30 years of clinical use. II. Mayo Clinic Proceedings 60, 271-8.